Evidence map›Paper›PMID 20706624›Full record

ArticlePloS one2010

Targeted Therapy Database (TTD): a model to match patient's molecular profile with current knowledge on cancer biology.

Simone Mocellin, Jeff Shrager, Richard Scolyer, Sandro Pasquali, Daunia Verdi, Francesco M Marincola, Marta Briarava, Randy Gobbel, Carlo Rossi, Donato Nitti

Abstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Systemic treatments for metastatic cutaneous melanoma.The Cochrane database of systematic reviews · 2018
    Pooled it
  2. Interferon alpha for the adjuvant treatment of cutaneous melanoma.The Cochrane database of systematic reviews · 2013
    Pooled it
  3. Article
  4. Review
  5. Adaptive Cancer Therapy in the Age of Generative Artificial Intelligence.Cancer control : journal of the Moffitt Cancer Center
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Simone MocellinClinica Chirurgica Generale 2, Department of Oncological and Surgical Sciences, University of Padova, Padova, Italy. simone.mocellin@unipd.it
Jeff Shrager
Richard Scolyer
Sandro Pasquali
Daunia Verdi
Francesco M Marincola
Marta Briarava
Randy Gobbel
Carlo Rossi
Donato Nitti

Funding

Immunogenetics of Vaccine TherapyZIACL002115 · CLC · CLINICAL CENTER · PI MARINCOLA, FRANCESCO M · 2009 to 2010
$0k
Immunogenetic Study of Infectious Diseases and CancerZIACL002118 · CLC · CLINICAL CENTER · PI MARINCOLA, FRANCESCO M · 2009 to 2012
$0k
6 · The paper itself

Abstract

backgroundThe efficacy of current anticancer treatments is far from satisfactory and many patients still die of their disease. A general agreement exists on the urgency of developing molecularly targeted therapies, although their implementation in the clinical setting is in its infancy. In fact, despite the wealth of preclinical studies addressing these issues, the difficulty of testing each targeted therapy hypothesis in the clinical arena represents an intrinsic obstacle. As a consequence, we are witnessing a paradoxical situation where most hypotheses about the molecular and cellular biology of cancer remain clinically untested and therefore do not translate into a therapeutic benefit for patients.

objectiveTo present a computational method aimed to comprehensively exploit the scientific knowledge in order to foster the development of personalized cancer treatment by matching the patient's molecular profile with the available evidence on targeted therapy.

methodsTo this aim we focused on melanoma, an increasingly diagnosed malignancy for which the need for novel therapeutic approaches is paradigmatic since no effective treatment is available in the advanced setting. Relevant data were manually extracted from peer-reviewed full-text original articles describing any type of anti-melanoma targeted therapy tested in any type of experimental or clinical model. To this purpose, Medline, Embase, Cancerlit and the Cochrane databases were searched. RESULTS AND

conclusionsWe created a manually annotated database (Targeted Therapy Database, TTD) where the relevant data are gathered in a formal representation that can be computationally analyzed. Dedicated algorithms were set up for the identification of the prevalent therapeutic hypotheses based on the available evidence and for ranking treatments based on the molecular profile of individual patients. In this essay we describe the principles and computational algorithms of an original method developed to fully exploit the available knowledge on cancer biology with the ultimate goal of fruitfully driving both preclinical and clinical research on anticancer targeted therapy. In the light of its theoretical nature, the prediction performance of this model must be validated before it can be implemented in the clinical setting.

Indexed as

Computational BiologyModels, BiologicalComputer SimulationData CollectionDrug Resistance, NeoplasmEvidence-Based MedicineHumansMelanomaNeoplasmsPrecision Medicine

Identifiers

PMID20706624
PMCPMC2919374

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.